Evaluation of a Tai Chi Resilience Training Program on Objective and Subjective Measures of Post Traumatic Stress Disorder Severity

April 10, 2023 updated by: Johns Hopkins University
The standard of care for PTSD involves both psychotherapy and pharmacotherapy, but treatment resistance is common. The discovery of effective complementary treatment approaches would have major implications for patients with PTSD. Mindfulness meditation and related practices have been studied intensively in recent years for a variety of psychiatric illnesses, including depression, generalized anxiety disorder, and PTSD. Studies in PTSD suggest that mindful meditation holds promise. For example, mindfulness-based stress reduction (MBSR) has shown effectiveness for reducing symptom severity and improving mental-health related quality of life in combat-exposed veterans and child survivors of sexual abuse. Mechanistically, mindfulness meditation appears to counteract the types of functional changes that have been identified in the brains of patients with PTSD. In particular, while PTSD symptoms are associated with decreased activation of the prefrontal cortex (PFC) and increased amygdala activity, mindfulness meditation is associated with increased PFC activation and decreased amygdala activation. Other physiological effects of mindfulness meditation in patients with PTSD are not fully defined. However, available data suggest that it leads to a normalization of vagal tone and plasma cortisol levels, which are known to be abnormal in patients with chronic PTSD. Research utilizing validated and standardized pre- and post- PTSD outcome measures, in addition to pre- and post- physiologic variables such a vagal tone, plasma cortisol and catecholamine levels, may better the understandings of physiological effects of mindfulness medication.

Study Overview

Detailed Description

Post-traumatic stress disorder (PTSD) affects an estimated 4.7% of the United States population every year, leading to increased rates of disability, suicide, substance use, and interpersonal difficulties. Mindfulness interventions for PTSD offer a low-cost, repeatable method that has the potential to induce fear extinction, and that has no known side effects. While several studies have reported the efficacy of mindfulness meditation and related mind-body exercises to reduce self-reported PTSD symptoms, little is known about the physiologic changes associated with mindfulness interventions. The present study seeks to evaluate the effects of a mind-body mindfulness intervention (tai chi) on subjective reports of PTSD symptoms, as well as physiologic correlates of PTSD in a population of law enforcement officers. Tai chi was chosen because its focus on awareness of physical movements is expected to provide an easier mindfulness target, as compared to traditional seated meditation. It is well documented that patients with PTSD, who frequently struggle with intrusive trauma-related memories, are often unable to attend to current circumstances, a problem that leads to exacerbation of symptoms. While there are promising preliminary data suggesting that tai chi leads to improvements in self-reported symptoms of PTSD, there are no data regarding the effects of tai chi on objective endocrine, physiological, and behavioral measures of PTSD.

The investigators hypothesize that the use of the mind-body practice of tai chi will lead to reductions in subjective self-report measures of PTSD as well a normalization of objective physiological correlates of PTSD. In particular, it is hypothesized that the efficacy of tai chi in the treatment of PTSD is hypothesized to be achieved by facilitating fear extinction and augmenting stress resilience through improved integration of mindfulness practices with daily physical activities. To test this hypothesis, the investigators propose the following specific aims:

• Specific Aim 1: To determine the self-reported symptom changes, behavioral changes, and physiological effects that take place during an 8-week intervention of simplified Tai Chi Moving Mindfulness Meditation and Resilience Training (TCMMMRT) in a population of police officers with and without self-reported PTSD. Results from these two groups will also be compared to a control group engaging in aerobic exercise.

  • Self-reported outcome measures: Brief Pain Inventory (BPI) short form, Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-V) (PCL-5), and Canadian Occupational Performance Measure (COPM).
  • Physiological outcome measures: Mobile Acoustic startle Reflex-monitoring System (MARS) measures, heart rate variability (HRV), cortisol measurements, and actigraphy to monitor sleep patterns and activity levels.

Study Type

Interventional

Enrollment (Actual)

63

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21224
        • Johns Hopkins Bayview Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

For inclusion as a healthy control or a participant with PTSD:

  • working in law enforcement
  • between the ages of 18 and 65
  • Both men and women

For inclusion as a participant with PTSD:

  • previously diagnosed with PTSD by a medical professional (For inclusion in the PTSD group)
  • Must meet criteria for PTSD as determined by the PCL-5 instrument on the day of initial assessment.

Exclusion criteria:

  • taking sedative or stimulant drugs daily
  • physical illness, injury, or disability preventing safe execution of low impact aerobic exercise

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TCMMMRT First
Participants will perform an instructor-led mind-body exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home practice will be logged. At the completion of the TCMMMRT Condition, participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week for a total of 8 weeks. Home exercise will be logged.
Low-impact mind-body exercise adapted from traditional tai chi.
Low-impact aerobic exercise, led by instructor
Active Comparator: Aerobic Exercise First
Participants will perform an instructor-led low impact aerobic exercise regimen 1 day per week during this arm of the study for a total of 8 weeks. Home exercise will be logged. At the completion of the aerobic exercise condition, participants will perform an instructor-led mind-body exercise regimen 1 day per week for a total of 8 weeks. Home practice will be logged.
Low-impact mind-body exercise adapted from traditional tai chi.
Low-impact aerobic exercise, led by instructor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in PCL-5 Score
Time Frame: Assessed on Day 1, Day 56, Day 112, and Day 168
Score on the PTSD Symptom Checklist for DSM-5. The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses the presence and severity of PTSD symptoms. Items on the PCL-5 correspond with DSM-5 criteria for PTSD. The PCL-5 can be used to quantify and monitor symptoms over time, to screen individuals for PTSD, and to assist in making a provisional or temporary diagnosis of PTSD.
Assessed on Day 1, Day 56, Day 112, and Day 168

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in BPI score
Time Frame: Assessed on Day 1, Day 56, Day 112, and Day 168
Brief Pain Inventory - a 9 item self-administered questionnaire used to assess pain severity and the affect of pain on daily functioning. Contains four measures of pain severity on a 0-10 scale and pain interference with 7 life activities on a 0-10 scale. It also includes items to specify pain location and treatments attempted. Across all numbered scales, higher numbers indicate more pain.
Assessed on Day 1, Day 56, Day 112, and Day 168
Change in BDI score
Time Frame: Assessed on Day 1, Day 56, Day 112, and Day 168
Beck Depression Inventory - a 21 item assessment of depressive symptoms. Raw score of 0-13 indicates minimal depression, 14 to 19 indicates mild depression, 20-28 indicates moderate depression, 29-63 indicates severe depression.
Assessed on Day 1, Day 56, Day 112, and Day 168
Change in PSQI score
Time Frame: Assessed on Day 1, Day 56, Day 112, and Day 168
Pittsburgh Sleep Quality Index - a 19 item assessment of different aspects of sleep that yields seven component scores and one component score. The composite scores range from 0 to 21, where lower scores denote a healthier sleep quality. Components are subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
Assessed on Day 1, Day 56, Day 112, and Day 168
Change in COPM score
Time Frame: Assessed on Day 1, Day 56, Day 112, and Day 168
Canadian Occupational Performance Measure - a semi-structured interview that enables assessment of occupational performance problems. It results in two scores of participant-perceived levels of occupational performance. It results in two main scores, performance and satisfaction, each out of 10, with higher numbers reflecting greater performance and satisfaction.
Assessed on Day 1, Day 56, Day 112, and Day 168
Change in Salivary Cortisol
Time Frame: Assessed on Day 1, Day 56, Day 112, and Day 168
Cortisol level in mcg/dL obtained from saliva sample.
Assessed on Day 1, Day 56, Day 112, and Day 168
Change in Heart Rate Variability
Time Frame: Assessed on Days 1, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91, 98, 105, 112, and Day 168
Heart Rate Variability collected using non-invasive Actigraph. Beat to beat intervals will be recorded by the device and output as the standard deviation of nearest neighbor (SDNN) and the square root of the means of the squares of the successive differences between adjacent nearest neighbors (RMSSD).
Assessed on Days 1, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91, 98, 105, 112, and Day 168
Change in Acoustic Blink Response
Time Frame: Assessed on Days 1, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91, 98, 105, 112, and Day 168
Response to an acoustic tone (milliseconds from tone to eye blink) collected using the Mobile Acoustic startle Reflex-monitoring System (MARS) device
Assessed on Days 1, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91, 98, 105, 112, and Day 168

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Una McCann, Johns Hopkins University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2021

Primary Completion (Actual)

July 27, 2022

Study Completion (Actual)

July 27, 2022

Study Registration Dates

First Submitted

February 26, 2020

First Submitted That Met QC Criteria

February 26, 2020

First Posted (Actual)

February 28, 2020

Study Record Updates

Last Update Posted (Actual)

April 11, 2023

Last Update Submitted That Met QC Criteria

April 10, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder

Clinical Trials on Tai Chi Moving Mindfulness Meditation and Resilience Training

Subscribe